US Pharma MarketingBioMarin spends up to $490m for Alesta’s bone disease candidate
BioMarin spends up to $490m for Alesta’s bone disease candidate is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The deal provides BioMarin with a potential rival to AstraZeneca’s blockbuster Strensiq in hypophosphatasia.
Source: Pharmaceutical Technology